CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement

Influenza and other Respiratory Viruses

Volumn 11, Issue 1, 2017, Pages 2-14

  Horby, Peter W ^a   Laurie, Karen L ^b   Cowling, Benjamin J ^c   Engelhardt, Othmar G ^d   Sturm Ramirez, Katharine ^e   Sanchez, Jose L ^f   Katz, Jacqueline M ^e   Uyeki, Timothy M ^e   Wood, John ^d   Van Kerkhove, Maria D ^g  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^e NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^f Armed Forces Health Surveillance Center (AFHSC) and Cherokee Nation Technology Solutions Inc   (United States)

^g INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHECKLIST; CONSENSUS; EPIDEMIOLOGICAL DATA; HUMAN; INFLUENZA; INFORMATION PROCESSING; MANDATORY REPORTING; METHODOLOGY; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; SEROEPIDEMIOLOGY; VALIDITY; CASE CONTROL STUDY; COHORT ANALYSIS; CONSENSUS DEVELOPMENT; CROSS-SECTIONAL STUDY; IMMUNOLOGY; INFLUENZA, HUMAN; PANDEMICS; STATISTICS AND NUMERICAL DATA;

CASE-CONTROL STUDIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; HUMANS; INFLUENZA, HUMAN; PANDEMICS; RESEARCH DESIGN; SEROEPIDEMIOLOGIC STUDIES;

EID: 84994633357     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12411     Document Type: Article

References (41)

1. Wong JY, Kelly H, Ip DK, Wu JT, Leung GM, Cowling BJ. Case fatality risk of influenza A (H1N1pdm09): a systematic review. Epidemiology 2013;24:830–841.
2. Lee VJ, Chen MI, Yap J, et al. Comparability of different methods for estimating influenza infection rates over a single epidemic wave. Am J Epidemiol. 2011;174:468–478.
3. Reed C, Katz JM. Serological surveys for 2009 pandemic influenza A H1N1. Lancet 2010;375:1062–1063.
4. Wu JT, Ho A, Ma ES, et al. Estimating infection attack rates and severity in real time during an influenza pandemic: analysis of serial cross-sectional serologic surveillance data. PLoS Med. 2011;8:e1001103.
5. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009;302:1872–1879.
6. Domínguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302:1880–1887.
7. Seroepidemiological studies of pandemic influenza A (H1N1) 2009 virus. Wkly Epidemiol Rec. 2010;85:229–235.
8. Van Kerkhove MD, Hirve S, Koukounari A, Mounts AW, Group HNpsw. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza Other Respir Viruses 2013;7:872–886.
9. Morens DM. Editorial commentary: pandemic H5N1: receding risk or coming catastrophe? Clin Infect Dis. 2013;56:1213–1215.
10. Wang TT, Parides MK, Palese P. Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science 2012;335:1463.
11. Toner ES, Adalja AA, Nuzzo JB, Inglesby TV, Henderson DA, Burke DS. Assessment of serosurveys for H5N1. Clin Infect Dis. 2013;56:1206–1212.
12. Mavrouli MD, Routsias JG, Maltezou HC, Spanakis N, Tsakris A. Estimation of seroprevalence of the pandemic H1N1 2009 influenza virus using a novel virus-free ELISA assay for the detection of specific antibodies. Viral Immunol. 2011;24:221–226.
13. Elizondo-Montemayor L, Alvarez MM, Hernandez-Torre M, et al. Seroprevalence of antibodies to influenza A/H1N1/2009 among transmission risk groups after the second wave in Mexico, by a virus-free ELISA method. Int J Infect Dis. 2011;15:e781–e786.
14. Boni MF, Chau NV, Dong N, et al. Population-level antibody estimates to novel influenza A/H7N9. J Infect Dis. 2013;208:554–558.
15. Meijer A, Bosman A, van de Kamp EE, Wilbrink B, Du Ry van Beest Holle M, Koopmans M. Measurement of antibodies to avian influenza virus A(H7N7) in humans by hemagglutination inhibition test. J Virol Methods 2006;2:113–120.
16. Dong L, Bo H, Bai T, et al. A combination of serological assays to detect human antibodies to the avian Influenza A H7N9 virus. PLoS One 2014;9:e95612.
17. Khurana S, Sasono P, Fox A, et al. H5N1-SeroDetect EIA and rapid test: a novel differential diagnostic assay for serodiagnosis of H5N1 infections and surveillance. J Virol. 2011;85:12455–12463.
18. Temperton NJ, Hoschler K, Major D, et al. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir Viruses 2007;1:105–112.
19. Van Kerkhove MD, Broberg E, Engelhardt OG, Wood J, Nicoll A. The consortium for the standardization of influenza seroepidemiology (CONSISE): a global partnership to standardize influenza seroepidemiology and develop influenza investigation protocols to inform public health policy. Influenza Other Respir Viruses 2013;7:231–234.
20. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453–1457.
21. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7:e1000251.
22. National Heart Lung and Blood Institute. Study Quality Assessment Tools. http://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools. 2014 (accessed 18 May 2015).
23. Reeves BC, Deeks JJ, Higgins JPT, Wells GA, On behalf of the Cochrane Non-Randomised Studies Methods Group. Part 3: Special topics. Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0, updated March 2011: The Cochrane Collaboration; 2011. Available at: http://handbook.cochrane.org/chapter_13/13_including_non_randomized_studies.htm. Accessed July 29 2016.
24. Van Kerkhove M, Wood J, CONSISE. Conclusions of the fourth CONSISE international meeting. Euro Surveill. 2014;19: pii: 20668.
25. Little J, Higgins JP, Ioannidis JP, et al. STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med. 2009;6:e22.
26. Yang S, Chen Y, Cui D, et al. Avian-origin influenza A(H7N9) infection in influenza A(H7N9)-affected areas of China: a serological study. J Infect Dis. 2014;209:265–269.
27. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945–1952.
28. Wu JT, Ma ES, Lee CK, et al. The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis. 2010;51:1184–1191.
29. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010;375:1100–1108.
30. Nishiura H, Chowell G, Castillo-Chavez C. Did modeling overestimate the transmission potential of pandemic (H1N1-2009)? Sample size estimation for post-epidemic seroepidemiological studies. PLoS One 2011;6:e17908.
31. Cauchemez S, Horby P, Fox A, et al. Influenza infection rates, measurement errors and the interpretation of paired serology. PLoS Pathog. 2012;8:e1003061.
32. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol. 2010;10:18.
33. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2003;115:63–73.
34. Wu JT, Leung K, Perera RA, et al. Inferring influenza infection attack rate from seroprevalence data. PLoS Pathog. 2014;10:e1004054.
35. Baguelin M, Hoschler K, Stanford E, et al. Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimation. PLoS One 2011;6:e17074.
36. Defang GN, Martin NJ, Burgess TH, et al. Comparative analysis of hemagglutination inhibition titers generated using temporally matched serum and plasma samples. PLoS One 2012;7:e48229.
37. Laurie KL, Engelhardt OG, Wood J, Van Kerkhove MD. Global seroepidemiology: value and limitations. In: Clinical Insights: Influenza Surveillance. London: eBook: Future Medicine Ltd. 2014:51–66. ISBN: 978-1-78084-360-5.
38. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999;37:937–943.
39. Achonu C, Rosella L, Gubbay JB, et al. Seroprevalence of pandemic influenza H1N1 in Ontario from January 2009-May 2010. PLoS One 2011;6:e26427.
40. Wood JM, Major D, Heath A, et al. Reproducibility of serology assays for pandemic influenza H1N1: Collaborative study to evaluate a candidate WHO International Standard. Vaccine 2012;30:210–217.
41. Stephenson I, Heath A, Major D, et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis. 2009;15:1252–1259.